Sunitinib induced nephrotic syndrome and thrombotic microangiopathy
Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor and platelet derived growth factor receptor. It is used for the treatment of metastatic renal cell carcinoma (RCC). Use of sunitinib has been associated with renal dysfunction...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications & Media Pvt Ltd
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621245/ |